However, studies highlight cost as an obstacle to widespread accessibility in some countries 

New survival data from the MIRASOL trial support the use of this antibody-drug conjugate as a preferred standard of care for patients with high folate receptor alpha tumour expression

While updated results from the DUO-O trial appear promising, they are not conclusive due to the study design

A multitude of new agents under development could finally offer meaningful treatment options to a patient population with high unmet need  

Results from the BEATcc study strongly support the use of first-line combination therapy for R/M CC in all patients

Phase III trial findings reveal significant improvements in PFS and OS rates, although the population studied may not be wholly indicative of high-risk disease 

In the KEYNOTE-A18 study, the combination of pembrolizumab and concurrent chemoradiotherapy significantly improved progression-free survival

Two studies presented by the French network TMRG-GINECO provide new insights into the treatment and quality of life of women with this rare cancer 

Sustained benefit of PARPi treatment may help to put the recent concerns on how and when to use these agents in women into context

Unfavourable overall survival data for PARP inhibitors in certain ovarian cancers prompts calls for caution in interpretation of the analyses and stimulates the search for surrogate measures of clinical benefit